Literature DB >> 20647389

When treating cancer, please don't forget hepatitis B.

Lindsay Y King1, Raymond T Chung.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20647389      PMCID： PMC3228019          DOI： 10.1634/theoncologist.2009-0282

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  24 in total

1.  National Institutes of Health Consensus Development Conference Statement: management of hepatitis B.

Authors:  Michael F Sorrell; Edward A Belongia; Jose Costa; Ilana F Gareen; Jean L Grem; John M Inadomi; Earl R Kern; James A McHugh; Gloria M Petersen; Michael F Rein; Doris B Strader; Hartwell T Trotter
Journal:  Ann Intern Med       Date:  2009-01-05       Impact factor: 25.391

2.  Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy.

Authors:  G Rossi; A Pelizzari; M Motta; M Puoti
Journal:  Br J Haematol       Date:  2001-10       Impact factor: 6.998

3.  Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors.

Authors:  W Yeo; P K Chan; S Zhong; W M Ho; J L Steinberg; J S Tam; P Hui; N W Leung; B Zee; P J Johnson
Journal:  J Med Virol       Date:  2000-11       Impact factor: 2.327

4.  Reactivation of chronic hepatitis B virus infection by cancer chemotherapy.

Authors:  J H Hoofnagle; G M Dusheiko; D F Schafer; E A Jones; K C Micetich; R C Young; J Costa
Journal:  Ann Intern Med       Date:  1982-04       Impact factor: 25.391

5.  Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy.

Authors:  George K K Lau; Harry H Y Yiu; Daniel Y T Fong; Hoi-Ching Cheng; Wing-Yan Au; Lydia S F Lai; Micheal Cheung; Hai-Ying Zhang; Albert Lie; Roger Ngan; Raymond Liang
Journal:  Gastroenterology       Date:  2003-12       Impact factor: 22.682

6.  Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy.

Authors:  Winnie Yeo; Paul K S Chan; Wing M Ho; Benny Zee; Kwok C Lam; Kenny I K Lei; Anthony T C Chan; Tony S K Mok; Jam J Lee; Thomas W T Leung; Sheng Zhong; Philip J Johnson
Journal:  J Clin Oncol       Date:  2004-03-01       Impact factor: 44.544

Review 7.  Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures.

Authors:  D Lavanchy
Journal:  J Viral Hepat       Date:  2004-03       Impact factor: 3.728

8.  Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study.

Authors:  Winnie Yeo; Paul K S Chan; Pun Hui; Wing M Ho; Kwok C Lam; Wing H Kwan; Sheng Zhong; Philip J Johnson
Journal:  J Med Virol       Date:  2003-08       Impact factor: 2.327

9.  Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation.

Authors:  George K K Lau; Ming-Liang He; Daniel Y T Fong; Angeline Bartholomeusz; Wing-Yan Au; Albert K W Lie; Stephen Locarnini; Raymond Liang
Journal:  Hepatology       Date:  2002-09       Impact factor: 17.425

10.  Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy.

Authors:  W Yeo; B Zee; S Zhong; P K S Chan; W-L Wong; W M Ho; K C Lam; P J Johnson
Journal:  Br J Cancer       Date:  2004-04-05       Impact factor: 7.640
View more
  1 in total

1.  Management of hepatitis B reactivation in patients receiving cancer chemotherapy.

Authors:  Yi-Wen Huang; Raymond T Chung
Journal:  Therap Adv Gastroenterol       Date:  2012-09       Impact factor: 4.409
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.